fda ends tirzepatide shortage Update: On December 19th the ruled the tirzepatide was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On GLP-1 Drugs: FDA “Re-Confirms” Decision

Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents

Together, they attack body fat from multiple angles while preserving the lean tissue that determines your metabolic rate and physical appearance

During this period, sexual changes are primarily driven by physical discomfort and neurochemical adjustment

My Experience I believe that all three can have pros and cons for a person with Hashimotos who is concerned about blood sugar balance, gut health, and weight management (please note that you should not take all three at once!)

Glucose Lowering Liraglutide was the first long-acting GLP-1RA to become available for the treatment of T2D, receiving market authorization in 2009 in the EU (137), 4 years after the short-acting GLP-1RA, exenatide, was first approved in the US (138)

doi:10.1056/NEJM198106183042504